Stock listing

NASDAQ:ANNX Annexon, Inc. Stock

Home listing (NASDAQ) of Annexon, Inc.

Follow Annexon, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ANNX

$3.10 USD -0.42 (-11.9%)

Close on Nov 20, 2026

Past year -27.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.07 – $3.37 USDNov 20, 2026
Volume
4.45M sharesNov 20, 2026
Market cap
$587.7M USDAt the close on Nov 20, 2026 · price × 189.6M shares outstanding
52-week range
$3.07 – $7.18 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13.55M USDMedian day 3.08M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Annexon, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ANNX · Home$3.10 USD-0.42 (-11.9%)4,454,126$3.37$3.37$3.07$3.52Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANNX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.10-0.42-11.9%$3.37$3.37$3.074,454,126
$3.52+0.05+1.4%$3.46$3.63$3.442,975,857
$3.47-0.10-2.8%$3.67$3.67$3.372,880,090
$3.57-0.35-8.9%$3.90$3.975$3.553,113,341
$3.92-0.05-1.3%$3.97$3.99$3.752,584,906
$3.97-0.22-5.3%$4.14$4.17$3.874,462,474
$4.19-0.02-0.5%$4.25$4.275$4.143,075,985
$4.21-0.02-0.5%$4.30$4.37$4.1054,596,063
$4.23+0.03+0.7%$4.26$4.325$4.152,815,581
$4.20+0.195+4.9%$4.05$4.29$4.042,621,896
$4.005-0.325-7.5%$4.29$4.355$3.834,358,605
$4.33+0.14+3.3%$4.255$4.52$4.1554,432,604
$4.19+0.25+6.3%$3.98$4.23$3.944,280,894
$3.94-0.11-2.7%$4.06$4.08$3.902,276,667
$4.05+0.04+1.0%$4.00$4.09$3.872,837,114
$4.01-0.03-0.7%$4.04$4.20$3.953,284,752
$4.04+0.28+7.4%$3.78$4.05$3.7164,010,595
$3.76+0.06+1.6%$3.72$3.835$3.682,964,361
$3.70-0.05-1.3%$3.80$3.86$3.662,647,455
$3.75-0.06-1.6%$3.78$3.85$3.642,575,383
$3.81-0.05-1.3%$3.85$3.97$3.783,665,144
$3.86+0.03+0.8%$3.85$4.07$3.844,948,347
$3.83-0.18-4.5%$4.02$4.059$3.786,370,037
$4.01+0.60+17.6%$3.65$4.03$3.4356,362,378
$3.41-0.19-5.3%$3.60$3.61$3.3555,240,000
$3.60-0.07-1.9%$3.70$3.82$3.502,653,800
$3.67-0.16-4.2%$3.79$3.85$3.664,042,900
$3.83-0.13-3.3%$3.96$3.96$3.783,420,500
$3.96-0.06-1.5%$4.02$4.055$3.951,926,800
$4.02+0.02+0.5%$3.97$4.135$3.972,385,000
$4.00-0.01-0.2%$3.99$4.035$3.8553,213,900
$4.01-0.02-0.5%$3.99$4.175$3.912,449,800
$4.03-0.17-4.0%$4.21$4.26$4.012,701,300
$4.20+0.01+0.2%$4.25$4.31$4.063,447,900
$4.19+0.07+1.7%$4.21$4.265$4.1054,019,500
$4.12-0.11-2.6%$4.18$4.38$4.123,919,100
$4.23+0.10+2.4%$4.19$4.27$4.054,409,400
$4.13+0.12+3.0%$4.00$4.237$3.943,706,500
$4.01+0.37+10.2%$3.85$4.08$3.7355,072,600
$3.64-0.16-4.2%$3.81$3.85$3.633,511,300
$3.80-0.07-1.8%$3.85$3.87$3.7252,022,400
$3.87-0.31-7.4%$4.18$4.19$3.812,421,000
$4.18-0.04-0.9%$4.28$4.34$4.132,000,200
$4.22-0.01-0.2%$4.27$4.358$4.124,183,400
$4.23+0.06+1.4%$4.16$4.31$4.134,940,200
$4.17+0.24+6.1%$3.922$4.22$3.9153,119,700
$3.93+0.01+0.3%$3.91$4.00$3.8754,513,900
$3.92-0.03-0.8%$3.93$3.975$3.792,960,600
$3.95+0.01+0.3%$3.97$4.035$3.882,896,000
$3.94-0.20-4.8%$4.195$4.195$3.923,935,100
$4.14-0.23-5.3%$4.33$4.33$4.044,204,100
$4.37-0.30-6.4%$4.60$4.66$4.345,528,400
$4.67-0.20-4.1%$4.76$4.785$4.642,139,500
$4.87+0.03+0.6%$4.81$4.905$4.791,227,500
$4.84-0.09-1.8%$4.93$5.04$4.7652,313,300
$4.93+0.04+0.8%$4.90$5.075$4.781,842,200
$4.89-0.05-1.0%$4.96$5.00$4.851,472,300
$4.94-0.03-0.6%$4.99$5.04$4.832,436,800
$4.97-0.28-5.3%$5.18$5.205$4.9451,618,600
$5.25+0.26+5.2%$5.00$5.32$4.913,022,700
$4.99-0.16-3.1%$5.13$5.175$4.9552,276,000
$5.15+0.09+1.8%$5.13$5.225$5.0852,941,791
$5.06-0.01-0.2%$5.05$5.13$4.803,378,232
$5.07-0.11-2.1%$5.24$5.275$5.021,428,500
$5.18-0.32-5.8%$5.41$5.465$5.1051,669,700
Ticker
NASDAQ:ANNX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Annexon, Inc. news

Annexon, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 119 in all · newest Nov 17, 2026 · oldest 2020
Calls
1 call with a replay · 1 with a transcript · latest Aug 12, 2026
Decks
23 decks · latest July 2026

Where Annexon, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ANNX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ANNXBOATSUnited StatesUSD

Valuation

Price/book 4.1× against a median of 1.9×: the highest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$423.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
1.63

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Olema Pharmaceuticals, Inc. · NASDAQ:OLMAUS$615.0MUS$204.6Mn/an/an/a1.7×n/a0.0×1.25
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.6Mn/a106×n/a2.9×n/a0.4×n/a
Design Therapeutics, Inc. · NASDAQ:DSGNUS$577.6MUS$371.5Mn/an/an/a2.9×n/a0.0×1.29
Cullinan Therapeutics, Inc. · NASDAQ:CGEMUS$577.1MUS$289.6Mn/an/an/a2.0×n/a0.0×1.45
Immix Biopharma, Inc. · NASDAQ:IMMXUS$577.0MUS$241.7Mn/an/an/a1.7×n/a0.0×1.60
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
DBV Technologies SA · EURONEXT:DBVUS$571.8MUS$430.7Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.3MUS$232.4Mn/a765×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Median of the othersUS$575.9MUS$283.7M76.4×1.9×−208.6%0.0×1.37

Forecasts

6 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
17.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.03 · 4 analysts

Team and board

Officers

OfficerRole
Douglas LovePRESIDENT & CHIEF EXECUTIVE OFFICER
Jennifer LewEVP & CHIEF FINANCIAL OFFICER
Jamie DananbergEVP & CHIEF MEDICAL OFFICER
Michael OverdorfEVP & CHIEF BUSINESS OFFICER
Ted YednockEVP & CHIEF INNOVATION OFFICER
Jung E. ChoiBOARD MEMBER CHIEF BUSINESS AND STRATEGY OFFICER GLOBAL BLOOD THERAPEUTICS
Linda FitzpatrickCHIEF HUMAN RESOURCES OFFICER
Rick ArtisCHIEF SCIENTIFIC OFFICER

Board

DirectorRole
Bettina M. CockroftBOARD MEMBER
Douglas LovePRESIDENT & CHIEF EXECUTIVE OFFICER
Jung E. ChoiBOARD MEMBER CHIEF BUSINESS AND STRATEGY OFFICER GLOBAL BLOOD THERAPEUTICS
Mark BlumenkranzBOARD MEMBER
Will WaddillLEAD INDEPENDENT DIRECTOR
William BJ JonesBOARD MEMBER
William H. CarsonBOARD MEMBER

Events

Calls

CallWhenStatus
Annexon (NASDAQ:ANNX) Q2 2026 Earnings CallWed, Aug 12, 2026 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−0.5%
Q2 2026Aug 12, 2026 · Before open−0.2%
Q1 2026May 7, 2026 · After close+3.1%
Q4 2025Mar 9, 2026+17.8%
Q3 2025Nov 10, 2025 · After close−0.3%
Q2 2025Aug 14, 2025 · After close+2.5%
Q1 2025May 12, 2025 · Before open+10.6%
Q4 2024Mar 24, 2025 · Before open+12.5%
Q3 2024Nov 14, 2024 · Before open−3.4%
Q2 2024Aug 12, 2024 · Before open+2.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open+2.5%
Q4 2023Mar 26, 2024 · After close+13.5%
Q3 2023Nov 13, 2023 · Before open+6.3%
Q2 2023Aug 7, 2023 · Before open+2.1%
Q1 2023May 8, 2023 · After close+4.6%
Q4 2022Mar 6, 2023 · Before open−6.8%
Q3 2022Nov 3, 2022 · Before open+1.1%
Q2 2022Aug 8, 2022 · After close+2.9%
Q1 2022May 9, 2022 · After close+23.1%
Q4 2021Mar 1, 2022 · After close−2.5%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (July 2026)Technical10 slidesJuly 2026
44th Annual J.P. Morgan Healthcare Conference 2026Conference26 slidesJan 14, 2026
11th Congress of the European Academy of Neurology 2025Conference8 slidesJune 2025
Technical Presentation (May 2025)Technical4 slidesMay 2025
American Academy of Neurology Annual Meeting 2025Conference14 slidesApril 2025
Technical Presentation (June 2024)Technical9 slidesJun 23, 2024
Technical Presentation (June 2024)Technical35 slidesJun 4, 2024
Technical Presentation (June 2024)Technical14 slidesJune 2024
Technical Presentation (June 2024)Technical13 slidesJune 2024
Investor Day (March 2024)Investor day56 slidesMar 4, 2024
All 23 decks
DeckKindSlidesDate
Technical Presentation (February 2024)Technical17 slidesFeb 10, 2024
Technical Presentation (February 2024)Technical23 slidesFeb 3, 2024
Technical Presentation (December 2023)Technical8 slidesDec 20, 2023
Technical Presentation (December 2023)Technical14 slidesDec 20, 2023
Technical Presentation (November 2023)Technical17 slidesNovember 2023
Investor Presentation (January 2023)Investor deck68 slidesJan 9, 2023
Investor Presentation (July 2022)Investor deck41 slidesJul 8, 2022
Technical Presentation (March 2022)Technical15 slidesMar 24, 2022
Technical Presentation (March 2022)Technical11 slidesMar 10, 2022
40th Annual J.P. Morgan Healthcare Conference 2022Conference26 slidesJan 10, 2022
ASRS 2021Conference12 slidesOctober 2021
2021 Peripheral Nerve Society (PNS) Annual MeetingConference17 slidesSeptember 2021
Investor Presentation (January 2021)Investor deck33 slidesJan 11, 2021

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$86.25M raised · US$2.6 a share · Goldman Sachs & Co. LLC +2
Dealers: Goldman Sachs & Co. LLC (co-lead), TD Cowen (co-lead), Wells Fargo Securities (co-lead)
Nov 14, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Jul 23, 2020.

Price
US$17.00 a share
Shares offered
14,750,000 shares of common stock
Offering size
US$250.8 million
Underwriters' option
Up to 2,212,500 more shares
Underwriters
J.P. Morgan, BofA Securities, Cowen · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceSep 18, 2019
Filed publiclyJul 2, 2020
Amended twiceNewest Jul 23, 2020
Shares registered with an exchangeJul 21, 2020
Declared effective by the SECJul 23, 2020
Final prospectus, with the priceJul 24, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 24, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00000000
Cost of revenue3.69M3.45M3.27M3.31M3.41M667.0K493.0K488.0K271.0K
Gross profit-3.69M-3.45M-3.27M-3.31M-3.41M-667.0K-493.0K-488.0K-271.0K
Research and development184.7M119.4M113.8M112.5M100.1M49.3M24.5M15.5M17.9M
Selling, general and administrative31.7M34.6M28.0M33.1M30.6M14.2M7.99M3.62M2.62M
Operating income-216.4M-154.1M-143.7M-145.6M-130.7M-63.5M-32.5M-19.1M-20.5M
Depreciation and amortization2.17M2.15M2.15M2.11M2.14M667.0K493.0K488.0K271.0K
EBITDA-214.2M-151.9M-141.6M-143.5M-128.6M-62.8M-32.0M-18.7M-20.2M
Interest expense3.65M2.14M04.66M00
Income before tax-206.7M-138.2M134.2M141.9M130.3M-63.4M-37.2M-18.3M-18.7M
Income tax0000-2.53M-667.0K4.00K1.00K1.00K
Net income-206.7M-138.2M-134.2M-141.9M-130.3M-63.4M-37.2M-18.3M-18.7M
Earnings per share, basic-1.34-1.01-1.77-2.60-3.40-4.15-88.30-1.60-0.49
Earnings per share, diluted-1.34-1.01-1.77-2.60-3.40-4.15-88.30

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents162.1M49.5M225.1M140.0M74.8M268.6M43.9M44.2M2.97M
Short-term investments76.3M262.5M34.6M102.6M167.9M82.6M
Receivables3.00K79.0K225.0K582.0K
Inventory-3.00K
Current assets242.2M316.5M263.9M248.1M247.7M354.0M45.4M45.7M4.89M
Property, plant and equipment10.6M12.6M14.8M16.8M17.8M1.94M2.14M2.35M2.82M
Total assets277.6M350.1M297.7M285.1M287.0M355.9M49.9M48.1M7.82M
Accounts payable14.9M10.4M5.49M7.42M11.2M3.73M2.37M1.27M1.52M
Current liabilities42.6M30.5M17.9M22.4M21.7M10.6M4.93M3.33M2.92M
Long-term debt0
Total debt029.0M31.4M32.9M34.6M107.2M49.0M
Total liabilities65.9M57.0M47.1M53.9M55.1M11.7M6.37M10.3M54.0M
Shareholders' equity211.6M293.1M250.6M231.2M231.9M344.3M-100.5M37.9M-46.2M
Shares outstanding149.4M109.4M78.4M47.7M38.6M38.2M433.7K11.5M38.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-186.4M-118.0M-121.1M-116.3M-106.1M-53.1M-28.4M-17.2M-19.3M
Capital spending-137.0K-15.0K-193.0K-6.53M-1.65M-464.0K-267.0K-17.0K-567.0K
Free cash flow-186.5M-118.0M-121.3M-122.8M-107.8M-53.6M-28.6M-17.2M-19.8M
Cash from investing190.1M-218.8M70.7M58.4M-88.2M-83.2M-267.0K-17.0K-567.0K
Cash from financing108.9M161.2M135.5M122.9M1.79M360.9M28.4M58.5M42.0K
Dividends paid-1.86M-102.5M
Share buybacks121.4M1.79M-5.19M30.0M58.5M42.0K
Change in cash112.6M-175.6M85.1M65.0M-192.6M224.6M-244.0K41.2M-19.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 12, 2026ResultsSEC
8-K · Current reportAug 10, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
8-K · Current reportAug 6, 2026Current reportSEC
8-K · Current reportJul 30, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 14, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2026Meeting noticeSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
S-3ASR · Registration statementMar 30, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 30, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
8-K · Current reportFeb 17, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
8-K · Current reportJan 14, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 21, 2025Big-stake noticeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
8-K · Current reportNov 14, 2025Material contractSEC
424B5 · ProspectusNov 13, 2025Offer documentSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Current reportSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 3, 2025Offer documentSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
8-K · Current reportMar 3, 2025ResultsSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeJan 31, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 10, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025Management or board changeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
S-8 · Registration statement for employee plansDec 19, 2024Offer documentSEC
8-K · Current reportDec 16, 2024Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
8-K · Current reportOct 21, 2024Current reportSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
144 · Notice of proposed saleOct 15, 2024Other filingsSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
S-8 · Registration statement for employee plansSep 27, 2024Offer documentSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
144 · Notice of proposed saleSep 5, 2024Other filingsSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipAug 30, 2024Insider tradeSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 16, 2024Other filingsSEC
CORRESP · Letter to the SECAug 13, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2024Other filingsSEC
S-3 · Registration statementAug 12, 2024Offer documentSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
8-K · Current reportAug 5, 2024Current reportSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
144 · Notice of proposed saleJul 15, 2024Other filingsSEC
144 · Notice of proposed saleJul 15, 2024Other filingsSEC
144 · Notice of proposed saleJul 15, 2024Other filingsSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC

This page holds 200 of 526 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Annexon, Inc.’s releases · as of Nov 14, 2026

Common shares
189,579,134
Fully diluted
189,879,134

Fully diluted

LineSharesAs of
Common shares189,579,134
Options and RSUs300,000Nov 14, 2026

Warrants and options

Lot
Stock options · US$3.92 · expire about Nov 2036

Share count over time

CountShares
Nov 22, 2026189,579,134

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity26.9MUS$114MSep 30, 2026
Redmile Group, LLC14.3MUS$60.4MSep 30, 2026
BlackRock14.3MUS$60.3MSep 30, 2026
Vanguard11.5MUS$48.6MSep 30, 2026
State Street9.49MUS$40.2MSep 30, 2026
Bvf Inc8.28MUS$35MSep 30, 2026
Mak Capital One LLC7.77MUS$32.9MSep 30, 2026
Ameriprise6MUS$25.4MSep 30, 2026
Bain Capital Life Sciences Investors, LLC4.44MUS$18.8MSep 30, 2026
Siren, L.L.C.4.36MUS$18.4MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Mpm Bioimpact LLC4.29MUS$18.1MSep 30, 2026
Geode Capital4.25MUS$18MSep 30, 2026
Qube Research & Technologies Ltd4.11MUS$17.4MSep 30, 2026
Goldman Sachs3.92MUS$16.6MSep 30, 2026
Woodline Partners LP3.9MUS$16.5MSep 30, 2026
Great Point Partners LLC3.5MUS$14.8MSep 30, 2026
Point72 Asset Management, L.P.3.38MUS$14.3MSep 30, 2026
Balyasny Asset Management L.P.3.37MUS$14.2MSep 30, 2026
Morgan Stanley3.21MUS$13.6MSep 30, 2026
Palo Alto Investors LP2.81MUS$11.9MSep 30, 2026
Bank of America2.45MUS$10.4MSep 30, 2026
Nuveen2MUS$8.44MSep 30, 2026
Catalio Capital Management, LP1.99MUS$8.4MSep 30, 2026
Arrowstreet Capital, Limited Partnership1.98MUS$8.37MSep 30, 2026
Dimensional1.92MUS$8.14MSep 30, 2026
Candriam S.C.A.1.68MUS$7.13MSep 30, 2026
Marshall Wace, LLP1.58MUS$6.69MSep 30, 2026
Schwab1.57MUS$6.64MSep 30, 2026
Sirios Capital Management L P1.55MUS$6.56MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.5MUS$6.34MSep 30, 2026
Northern Trust1.4MUS$5.91MSep 30, 2026
Y-Intercept (Hong Kong) Ltd1.3MUS$5.49MSep 30, 2026
Kennedy Capital Management LLC1.29MUS$5.47MSep 30, 2026
Sphera Funds Management LTD.1.22MUS$5.17MSep 30, 2026
Acorn Capital Advisors, LLC1.14MUS$4.81MSep 30, 2026
Citadel1.13MUS$4.8MSep 30, 2026
Ishara Investments LP1.12MUS$4.74MSep 30, 2026
Panagora Asset Management Inc1.06MUS$4.47MSep 30, 2026
Wells Fargo1.02MUS$4.29MSep 30, 2026
Hrt Financial LP1MUS$4.25MSep 30, 2026
JPMorgan963KUS$3.98MSep 30, 2026
Opaleye Management Inc.875KUS$3.7MSep 30, 2026
UBS851KUS$3.6MSep 30, 2026
Algert Global LLC836KUS$3.54MSep 30, 2026
Ensign Peak Advisors, Inc739KUS$3.13MSep 30, 2026
Tetragon Partners GP Ltd656KUS$2.77MSep 30, 2026
Squarepoint Ops LLC651KUS$2.75MSep 30, 2026
Hennion & Walsh Asset Management, Inc.620KUS$2.62MSep 30, 2026
Trexquant Investment LP618KUS$2.61MSep 30, 2026
DWS603KUS$2.55MSep 30, 2026

This page holds 50 of 198 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF6.23MUS$35.6MJun 30, 2026
Select Biotechnology Portfolio5.08MUS$27.5MMay 31, 2026
Vanguard Total Stock Market Index Fund4.97MUS$28.4MJun 30, 2026
iShares Russell 2000 ETF4.06MUS$23.2MJun 30, 2026
Fidelity Stock Selector Small Cap Fund2.07MUS$10.5MJul 31, 2026
Fidelity Small Cap Growth Fund1.79MUS$9.11MJul 31, 2026
Vanguard Extended Market Index Fund1.75MUS$10MJun 30, 2026
Fidelity Small Cap Index Fund1.7MUS$8.64MJul 31, 2026
Fidelity Advisor Biotechnology Fund1.66MUS$8.47MJul 31, 2026
iShares Russell 2000 Growth ETF1.43MUS$8.17MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Columbia Small Cap Value Discovery Fund1.39MUS$7.08MJul 31, 2026
Select Health Care Portfolio1.2MUS$6.5MMay 31, 2026
Fidelity Series Small Cap Opportunities Fund1.19MUS$6.05MJul 31, 2026
iShares Biotechnology ETF1.01MUS$5.76MJun 30, 2026
Select Pharmaceuticals Portfolio1MUS$5.44MMay 31, 2026
Fidelity Small Cap Discovery Fund978KUS$4.98MJul 31, 2026
Columbia Acorn Fund976KUS$5.57MJun 30, 2026
Fidelity Small Cap Growth K6 Fund927KUS$4.72MJul 31, 2026
Nuveen Quant Small Cap Equity Fund925KUS$4.71MJul 31, 2026
Fidelity Series Small Cap Discovery Fund842KUS$4.29MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account840KUS$4.8MJun 30, 2026
Fidelity Advisor Health Care Fund750KUS$3.82MJul 31, 2026
Fidelity Enhanced Small Cap Core ETF710KUS$4.05MJun 30, 2026
Fidelity Extended Market Index Fund696KUS$3.77MMay 31, 2026
Vanguard Russell 2000 Index Fund677KUS$3.67MMay 31, 2026
MFS New Discovery Fund668KUS$3.62MMay 31, 2026
Schwab U.S. Small-Cap ETF638KUS$3.46MMay 31, 2026
Nuveen Quant Small/Mid Cap Equity Fund554KUS$2.82MJul 31, 2026
iShares Micro-Cap ETF520KUS$2.97MJun 30, 2026
Fidelity Small Cap Stock Fund469KUS$2.39MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund466KUS$2.53MMay 31, 2026
Vanguard U.S. Momentum Factor ETF452KUS$2.45MMay 31, 2026
Schwab Small-Cap Index Fund376KUS$1.92MJul 31, 2026
U.S. Small Cap Portfolio374KUS$1.91MJul 31, 2026
Vanguard Health Care Index Fund356KUS$1.93MMay 31, 2026
Dimensional U.S. Small Cap ETF327KUS$1.66MJul 31, 2026
Vanguard Explorer Fund320KUS$1.63MJul 31, 2026
Fidelity Fundamental Small-Mid Cap ETF311KUS$1.59MJul 31, 2026
Master Small Cap Index Series290KUS$1.66MJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund287KUS$1.46MJul 31, 2026
U.S. Micro Cap Portfolio273KUS$1.39MJul 31, 2026
JPMorgan U.S. Small Company Fund272KUS$1.55MJun 30, 2026
Fidelity Total Market Index Fund263KUS$1.42MMay 31, 2026
Columbia Variable Portfolio - Small Cap Value Discovery Fund252KUS$1.44MJun 30, 2026
Invesco Dorsey Wright SmallCap Momentum ETF247KUS$1.34MMay 31, 2026
MFS New Discovery Series233KUS$1.33MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF219KUS$1.11MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF218KUS$1.25MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares212KUS$1.08MJul 31, 2026
Nuveen Small Cap Blend Index Fund206KUS$1.05MJul 31, 2026

This page holds 50 of 195 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Carson William H.
Director
Buy34,000USD 3.58US$122KNov 19, 2026
Love Douglas
Director, Officer: PRESIDENT AND CEO
Buy26,065USD 3.83US$99,829Sep 24, 2026
Satter Muneer A
Director
Buy613,497USD 5.41US$3.32MMay 28, 2026
Carson William H.
Director
Buy8,000USD 5.78US$46,240May 11, 2026
Carson William H.
Director
Buy8,000USD 6.20US$49,600Apr 10, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC13.90%26.3MSep 30, 2026Schedule 13G
Redmile Group, LLC9.90%17.9MJul 1, 2026Schedule 13G
BlackRock, Inc.8.00%13.1MJun 30, 2026Schedule 13G
Satter Muneer A7.20%10.4MNov 19, 2025Schedule 13D
State Street Corp6.00%9.82MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carol G. Gallagher
Other companies: TRex Bio, Inc. (Lead Independent Director · Since at least Nov 5, 2026); PMV Pharmaceuticals, Inc. (Director · Since at least Nov 3, 2022); Atara Biotherapeutics, Inc. (Director · Since at least Jun 27, 2019); Certara, Inc. (Director · Jun 15, 2021 – Jun 15, 2021 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Metacrine Inc (Director · Sep 15, 2020 – Sep 15, 2020 · Past); Turning Point Therapeutics Inc (Director · Jul 24, 2019 – Aug 17, 2022 · Past); Tempest Therapeutics, Inc. (Director · Jun 20, 2019 – Jun 22, 2020 · Past)
Director · Jul 23, 2020 – Jul 23, 2020 · Past
Thomas Wiggans
Other companies: Pacira BioSciences, Inc. (Director · Since at least Jun 9, 2026); Jasper Therapeutics, Inc. (Chairman of the Board · Since at least Nov 1, 2023); Pardes Biosciences Inc (Chief Executive Officer, Director · Mar 1, 2022 – Aug 31, 2023 · Past); Forma Therapeutics Holdings Inc (Director · Sep 7, 2020 – Oct 14, 2022 · Past); Somaxon Pharmaceuticals Inc (Director · Jun 11, 2008 – Jul 2, 2012 · Past); Sangamo Therapeutics, Inc. (Director · Jun 4, 2008 – Jun 1, 2011 · Past); Onyx Pharmaceuticals Inc (Director · Aug 29, 2007 – Oct 1, 2013 · Past)
Director · Since at least Jul 23, 2020
William Waddill
Other companies: Arrowhead Pharmaceuticals, Inc. (Director · Since at least Dec 20, 2017); Protagonist Therapeutics, Inc. (Independent Director · Since at least Aug 10, 2016); Turnstone Biologics Corp. (Director · Apr 15, 2024 – Jun 3, 2024 · Past); Calithera Biosciences, Inc. (SR. VP & CFO · Oct 1, 2014 – Nov 29, 2016 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Financial Officer · Jul 17, 2013 – Jul 23, 2013 · Past)
LEAD INDEPENDENT DIRECTOR · Since at least Aug 12, 2021
Muneer A Satter
Other companies: Rein Therapeutics, Inc. (See Remarks, Director · Jun 8, 2020 – Jan 8, 2021 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Immunic, Inc. (Director · Apr 16, 2014 – Sep 13, 2018 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past)
Director · Since at least Jul 23, 2020
Jennifer Lew
Other companies: Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Aduro Biotech Inc (Chief Financial Officer · Apr 14, 2015 – May 1, 2019 · Past); Dynavax Technologies Corporation (VP, Finance & PAO · Jan 31, 2012 – Feb 5, 2013 · Past)
EVP & CHIEF FINANCIAL OFFICER · Since at least Jul 23, 2020
Ricky Sun
Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Jun 9, 2021 · Past); Savara, Inc. (Director · Dec 24, 2019 – Dec 14, 2023 · Past)
Director · Jul 23, 2020 – Jun 2, 2021 · Past
William H. Carson
Other companies: Decibel Therapeutics Inc (Director · Jun 2, 2021 – Sep 25, 2023 · Past); Prevail Therapeutics Inc (Director · Sep 9, 2020 – Jan 22, 2021 · Past)
BOARD MEMBER · Since at least Feb 5, 2021
Bettina M. Cockroft
Other companies: CNS Pharmaceuticals, Inc. (Director · Since at least Nov 17, 2025)
BOARD MEMBER · Since at least Jun 5, 2025
Jamie Dananberg
Other companies: Unity Biotechnology Inc (Chief Medical Officer · May 2, 2018 – Mar 31, 2023 · Past)
EVP & CHIEF MEDICAL OFFICER · Since at least Jul 27, 2023
Dean Richard ArtisEVP & CHIEF SCIENTIFIC OFFICER · Since at least Jan 6, 2023
All 20 people
PersonSeat
Douglas LovePRESIDENT & CHIEF EXECUTIVE OFFICER · Since at least Feb 19, 2026
Jung E. ChoiDirector · Since at least Jun 5, 2025
Larry MattheakisEVP & Chief Scientific Officer · Sep 30, 2021 – Jul 11, 2022 · Past
Linda FitzpatrickCHIEF HUMAN RESOURCES OFFICER · Since at least Nov 5, 2026
Lloyd Clarksenior vice president, ophthalmology strategy and innovation · Jun 18, 2025 – Nov 5, 2026 · Past
Mark BlumenkranzDirector · Since at least Aug 10, 2026
Michael OverdorfEVP & CHIEF BUSINESS OFFICER · Since at least Jul 14, 2025
Rick ArtisCHIEF SCIENTIFIC OFFICER · Since at least Nov 5, 2026
Ted YednockEVP & CHIEF INNOVATION OFFICER · Since at least Jul 23, 2020
William JonesBOARD MEMBER · Since at least Jan 10, 2025

Open People

Log in to ask 6ix AI your own questions about Annexon, Inc.